Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in haemophilia;Behandeling en preventie van bloedingen met recombinant-geactiveerde-factor VII, niet alleen bij hemofilie

Nederlands Tijdschrift voor Geneeskunde

Volumn 146, Issue 52, 2002, Pages 2534-2537

  Levi, M ^a   Friederich, Ph W ^a   Van Der Meer, J ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HEMOPHILIA; HUMAN; PERIOPERATIVE PERIOD;

AUTOANTIBODIES; BLOOD LOSS, SURGICAL; FACTOR VIIA; HEMOPHILIA A; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS;

EID: 0037192064     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cate H ten, Levi M, Hack CE. Nieuwe inzichten en hypothesen met betrekking tot de werking van de bloedstolling in vivo. Ned Tijdschr Geneeskd 1993;137:282-7.
2. Levi M, Vink R, de Jonge E. Pro-hemostatic therapy for prevention and treatment of bleeding. In: Vincent JL, editor. Yearbook of Intensive Care and Emergency Medicine. Berlijn: Springer; 2002. p. 649-60.
3. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patiënts with inherited and acquired bleeding disorders. Transfusion Medicine Reviews 1993; 7:78-83.
4. Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, et al. Successful use of recombinant factor VIIa in patiënt with severe haemophilia A during synovectomy. Lancet 1988;2:1193.
5. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998;4:790-8.
6. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-8.
7. Laurian Y, Goudemand J, Negrier C, Vicariot M, Marques-Verdier A, Fonlupt J, et al. Use of NovoSeven(r) as first line therapy for bleeding episodes in hemophiliacs with factor VIII or IX inhibitors (Nosepac study). Thromb Haemost 1997;77:85.
8. Turkstra F, Levi M, Koopman MMW, Wester JPJ, Stoutenbeek CP, Briët E. Recombinantfactor VIIa (eptacog alfa): Nieuwe therapeutische optie bij patiënten met een ernstige bloeding door antistoffen tegen een stollingsfactor. Ned Tijdschr Geneeskd 1998;142:1464-7.
9. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost 1997;78:1463-7.
10. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Haemost 2000;26:425-32.
11. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996;75:981-2.
12. Peters M, Heijboer H. Treatment of a patiënt with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998;80:352.
13. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000;83: 634-5.
14. Friederich PW, Wever PC, Briët E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001;66:292-4.
15. Mauser-Bunschoten EP, Goede-Bolder A de, Wielenga JJ, Levi M, Peerlinck K. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med 1998;53:249-55.
16. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterol 1997; 113:1930-7.
17. Hendriks HG, Meijer K, Wolf JT de, Klompmaker U, Porte RJ, Kamp PJ de, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study. Transplantation 2000;402-5.
18. Planinsic RM, Testa G, Emre S, Grande L, Meer J van der. Use of NovoSeven in patients undergoing orthotopic liver transplantation. Proceedings of the 6th NovoNordisk Symposium on Bleeding and Thrombotic Disorders. Charlottesville: Carden Jennings Publishing Corporation; 2001. p. 34-5.
19. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Btiller M, Levi M. The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: The PROSE study. Lancet [ter perse].
20. Martinowitz U, Holcomb JB, Pusateri AE, Stein M, Onaca N, Freidman M, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001;50:721-9.
21. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-8.
22. Al Douri M, Shafi T, Al Kudairi D, Al Bokhari E, Black L, Akinwale N, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000;11(Suppl 1): S121-7.
23. White B, McHale J, Ravi N, Reynolds J, Stephens R, Moriarty J, et al. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999;107:677-8.
24. Kamphuisen PW, Akker JM van den, Kaasjager KA, Bloemen TI. Control of life-threatening pulmonary bleeding with activated recombinant factor VII. Am J Med 2002;112:332-3.
25. Moscardo F, Perez F, de la Rubia, Balerdi B, Lorenzo JI, Senent ML, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001;114:174-6.
26. Hendriks HG, Maaten JM van der, Wolf JT de, Waterbolk TW, Slooff MJ, Meer J van der. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001;93:287-9.
27. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001;103:2555-9.
28. Bijsterveld NR, Moons AH, Boekholdt SM, Aken BE van, Fennema H, Peters RJ, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106:2550-4.
29. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999;82:1775-6.
30. Roberts HR. Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol 2001;38:48-50.
31. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-8.